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Abstract

Approximately 16.3% of the adult population in the United States maintains elevated
levels of total cholesterol, and the components of the cholesterol profile—HDL, LDL, and
triglyceride levels, among others—are particular determinants of cardiovascular disease risk.
High levels of LDL in particular are associated with coronary atherosclerosis and cardiovascular
disease. Conversely, high levels of HDL remove cholesterol from the blood and aid in
metabolism. The HDL/LDL ratio is considered a marker of carotid plaque and is specifically
used as an indicator for cardiovascular disease risk. Traditional cholesterol control treatment
utilizes statin therapy and antihypertensive medication; however, recent trends toward alternative
methods of treatment are making holistic cholesterol treatment programs more well-known.
Using archival patient records at a holistic health cholesterol treatment program, this study
investigates changes over the course of treatment in total cholesterol levels, the HDL/LDL ratio,
and other cardiovascular health-related variables such as blood pressure, pulse rate, and weight.
This study will provide a basis for future research investigating cardiovascular health from a
holistic perspective, rather than examining these factors in isolation.
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Cholesterol Levels and Cardiovascular Health Indicator Changes in a Holistic Health
Treatment Program: An Archival Study
The Centers for Disease Control and Prevention estimates that 16.3% of the adult
population in the United States has high total cholesterol—defined as total cholesterol 240
mg/dL and above (CDC, 2010). While the prevalence of high cholesterol in the adult
demographic has been declining in recent decades (Schober, Carroll, Lacher, & Hirsch, 2007),
this problem continues to be of significant economic and therapeutic concern; more than $300
billion is spent on cardiovascular care each year in the United States (HHS.gov, 2011), and
25.4% of deaths in 2007 were attributable to cardiovascular disease alone (CDC, 2007).
Although the regulation of blood pressure levels may reduce the need for traditional cholesterolcontrolling medications (Green et al., 2002), those who maintain high levels of cholesterol
sustain approximately twice the risk of coronary heart disease (CHD) as those with optimal
levels (CDC, 2010). Low-density lipoprotein (LDL) cholesterol in particular leads to
accumulated coronary atherosclerosis (Scann, 1978 in Tian et al., 2011). Thus, the components
of the cholesterol profile—HDL, LDL, and triglyceride levels, among others—are particularly
crucial to note when determining cardiovascular disease (CVD) risk.
Treatment of Cholesterol
Traditionally, elevated cholesterol levels have been treated with statin and
antihypertensive regimens (Boden, 2003; Van der Harst & de Boer, 2010). However, current
statin treatments focus on lowering LDL levels rather than on increasing HDL levels, and often
produce undesireable side-effects (Anderson & Taylor, 2011; Rea, Durrant, & Boldy, 2002).
While there has been demonstrated clinical improvement in cholesterol levels due to statin
therapy, 60-70% of cardiovascular events are not prevented even with its use (Stroes, 2005).

	
  

CHOLESTEROL CHANGES

4

Recently, there has been a trend towards a more holistic perspective of total body health, and
holistic cholesterol treatment programs are becoming a viable alternative to traditional treatment
(Guarneri, Mercado, & Suhar, 2009; Pratt, 2010). Holistic programs are extremely varied and
differ from one program to another; however, focus is usually directed towards effecting lifestyle
changes such as diet, exercise, and stress management rather than on the use of medications. The
American Heart Association affirms that lifestyle changes such as these decrease cardiovascular
disease morbidity and mortality risk (Artinian et al., 2010).
Low-Density Lipoprotein
Low-density lipoprotein cholesterol (LDL) is a combination protein-and-lipid whose
composition is low in protein and high in cholesterol, and which transports cholesterol from the
liver to the body tissues. High levels of LDL in the body are a direct cause of accumulated
coronary atherosclerosis (Scann, 1978 in Tian et al., 2011). In the United States, 33.5% of adults
maintain elevated levels of LDL; only 48.1% of these are receiving treatment (Morbidity and
Mortality Weekly Report, 2011). High levels of non-HDL cholesterol have been linked to
increased coronary heart disease-related mortality, and incidence of stroke (Li et al., 2011). In
patients diagnosed with diabetes, high non-HDL levels (i.e. levels greater than 5.3 mmol/L) were
associated with a 40% increased risk of death from CHD (Laasko, Lehto, Penttila, & Pyorala,
1993 in Li et al., 2011).
High-Density Lipoprotein
High-density Lipoprotein cholesterol (HDL) is comprised of a relatively large proportion
of protein and little cholesterol. As HDL removes cholesterol from the blood, prevents the
cellular uptake of LDL, and aids in metabolism of other lipoproteins, high levels of serum HDL
are associated with a reduced risk of CHD (Wilson et al., 1998 in Tian et al., 2011). One study
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defined low levels of HDL as <40 mg/dL in men and <50 mg/dL in women (Ingelsson et al.,
2009). Although the National Cholesterol Education Program has not set a specific goal value for
raising HDL levels, the limited HDL level-raising properties of statin medication may be of
particular concern for the one-third of patients with CVD who have normal serologic LDL levels
but low HDL levels (Melnikova, 2005).
HDL/LDL Ratio
The HDL/LDL ratio is considered a marker of carotid plaque and cardiovascular health
regardless of total cholesterol levels, and is used as a more accurate indicator for cardiovascular
disease risk than LDL levels alone (Awano, 2010; Kannel, 2007, Millán et al., 2009). The
HDL/LDL ratio is a strong predictor for subclinical atherosclerosis and carotid intima-media
thickness progression (Enomoto et al., 2011). There is some evidence that the effectiveness of
lipoprotein ratio profiles as an indicator of cardiovascular disease risk may differ by age
(Paramsothy et al., 2010). While there is a growing trend towards using apolipoprotein levels as
more accurate predictors of CVD risk than cholesterol levels, the HDL/LDL ratio is still
considered a viable and standard method of assessing risk and cardiovascular health (Fernandez
& Webb, 2008).
The Program
The holistic cholesterol and diabetes health program under study focuses on transforming
lifestyle through dietary intake, exercise, moderation, outdoor activity, adequate rest, and trust in
God. Patients are enrolled in an 18 day treatment program with individualized meal plans, an
exercise regimen, physical therapy including water treatments and steam baths, and time for
social interaction. Physical exams with a medical doctor are conducted throughout the program
to assess changes over treatment.
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Traditional treatment programs for cholesterol primarily utilize statin therapy and
antihypertensive medication (Green, Kwok, & Durrington, 2002). However, there is growing
evidence that balanced diets which include cereals, fruits, vegetables, and proteins improve
cardiovascular health. Lifestyle factors such as diet have specifically been shown to have a
measureable effect on plasma cholesterol levels (Howard et al., 2006). In one study, HDL
improved more on a low–glycemic load diet (40% carbohydrate and 35% fat), and LDL
concentration improved more on a low-fat diet (55% carbohydrate and 20% fat; Ebbeling et al.,
2007). Evidence has suggested that CHD progression responses to diet differ by gender, age, and
initial cholesterol levels (Lapointe, Balk, & Lichtenstein, 2006; Uranga & Keller, 2010; Schober
et al., 2007). Dietary intake of soy protein has been shown to reduce LDL levels and lessen the
need for cholesterol-lowering treatments such as statin medications (Grunwald, Hoie, & Stier,
2009). A diet rich in anti-oxidant vitamins, phytochemicals, folate, and dietary fiber provides
“substantial additional benefits to diets low in saturated fatty acids” (Noakes, Clifton, &
McMurchie, 1999, p. S3).
The Study
This study describes the outcomes of such a holistic program (name withheld for
confidentiality), examines the relationships between cardiovascular health-related variables, and
provides a basis for future research investigating these health markers from a holistic
perspective, rather than in isolation. Specifically, this study evaluated the changes in total
cholesterol levels and HDL/LDL ratios due to the holistic health treatment program, and
identified demographic profiles and other cardiovascular health-related variables which are
related to this change. This study examined the efficacy of alternative treatments, providing
patients with elevated cholesterol a basis for choosing a holistic program.
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Materials and Methods

This is an archival analysis of patient records collected during pre- and post-treatment
physical exams. All data were collected over six years (1998-2003) using standardized patient
charting procedures. Cholesterol, triglycerides, HDL and LDL levels (mg/dL), pulse rate (bpm),
blood pressure (mmHg), weight (lbs), amount of exercise (miles/day), age (years), and gender
were included in the analysis. All statistical tests were performed using PASW SPSS Statistics
Student Version 18. All records were kept confidential as per the American Psychological
Association’s Ethical Principles of Psychologists and Code of Conduct (APA.org, 2010).
The study population was composed of 901 patients (549 women, 352 men) enrolled in
the program. Mean age of the sample was 60.80 years (SD = 15.26). Initial cholesterol and
cardiovascular health variable data are listed in Table 1. In quite a few cases, some data points
were missing from the archive; however, data were complete for all variables in 502 cases. Three
relationships were analyzed in this study: change evidenced due to treatment, the relationship
between total cholesterol and additional cardiovascular health variables, and the relationship
between the HDL/LDL ratio and additional cardiovascular health variables. Variables were
tested and analyzed using the t-statistic for independent samples, the t-statistic for paired
samples, the Pearson Product-Moment Correlation Coefficient, and linear regression as
appropriate.
Results
Significant differences between genders were seen for initial total cholesterol, HDL,
LDL, the HDL/LDL ratio, and weight. Of these significant differences, men had higher
triglyceride levels and initial weight than did women; however, women had higher total
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cholesterol, HDL, LDL, and HDL/LDL ratio values. For a summary of gender differences in
cardiovascular health variables at admittance, see Table 2.
As the statistical results of this study are numerous and as analysis covers several topics,
the results section of this report first details a summary of overall changes evidenced over the
course of treatment. Following this, the relationships between cardiovascular-health related
variables and (a) initial total cholesterol, (b) total cholesterol change, (c) initial HDL/LDL ratio,
and (d) HDL/LDL ratio change are described. Total cholesterol levels are used as a reference
marker and the HDL/LDL ratio is analyzed as an indicator of cardiovascular health and relative
CVD risk.
Overall Changes Evidenced
Over the course of the 18 day treatment, there was a significant improvement in all major
cardiovascular health variables except HDL levels. Total cholesterol improved from M = 198.20
mg/dL (SD = 46.58) to M = 174.50 mg/dL (SD = 42.21). Triglycerides dropped from M = 182.53
mg/dL (SD = 118.47; kurtosis = 23.73) to M = 154.81 (SD = 76.25; kurtosis = 12.30); both initial
and discharge triglyceride levels exhibited an unusually large kurtosis value, which indicated a
large spread of triglyceride scores around the mean. Mean LDL levels decreased from 114.42
mg/dL (SD = 36.92) to 98.25 (SD = 33.07). Contrary to expected trends, mean HDL levels also
decreased from 47.94 mg/dL (SD = 14.18) to 45.34 mg/dL (SD = 13.25). However, the overall
HDL/LDL ratio mean improved from 0.471 (SD = 0.23) to 0.514 (SD = 0.25). Upon regression
analysis, this overall HDL/LDL ratio improvement and the concurrent decrease in both total
cholesterol and in LDL levels explained 43% of the observed decline in HDL levels (R2 = .430,
F(3, 699) = 177.204, SE = 5.749, p < .001; for a summary of interactions, see Table 3).
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Other cardiovascular health marker variables also improved over the course of treatment.
Mean systolic blood pressure improved from 141.90 mmHg at admittance (SD = 24.50) to
127.50 mmHg at discharge (SD = 19.85). Similarly, diastolic blood pressure decreased from
admittance (M = 80.17; SD = 14.61) to discharge (M = 73.19; SD = 10.80). The mean amount of
exercise in which patients engaged rose from 0.85 miles/day (SD = 1.44) at the beginning of
treatment to 3.53 miles/day (SD = 2.26) by the end of the program. Over the course of the 18 day
treatment, mean patient weight decreased from 206.10 lbs at initial evaluation (SD = 61.86) to
200.33 lbs at discharge (SD = 59.06). All differences noted were statistically significant (see
Table 4).
Initial Total Cholesterol
Upon deeper analysis of total cholesterol dynamics, several relationships were noted
between initial cholesterol levels and other holistic cardiovascular health variables. Initial
cholesterol levels were analyzed by gender and age categories to see whether there was a
significant difference between groups at the beginning of treatment. A significant gender
difference for total initial cholesterol was present (t(837) = 4.988, p < .001); men had lower
initial cholesterol levels (M = 187.33 mg/dL, SD = 47.03) than did women (M = 203.90 mg/dL,
SD = 46.57). Additionally, cholesterol levels were compared by age groups (defined as 10 year
increments from 20 to 99 years of age). Patients age 40-49 had the highest mean admittance
cholesterol levels of any age group (n = 119, M = 204.06, SD = 60.96), and the second highest
age group, those 50-59, had mean cholesterol levels of 203.64 mg/dL (n = 194, SD = 47.91).
Patients ages 90-99 evidenced the lowest mean initial cholesterol (n = 7, M = 176.14, SD =
56.07). For a summary of initial cholesterol age group differences see Figure 1.
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Relationships with other cardiovascular health variables such as blood pressure, weight,
and pulse rate were also analyzed to see whether any relationship existed between these variables
and initial levels of cholesterol. These observed relationships describe the profile of those
patients with higher admittance levels of cholesterol and evidence concurrent lower overall
cardiovascular health markers as seen from a holistic perspective. Although positive
relationships were noted between initial total cholesterol levels and several cardiovascular health
markers, because of the large sample size and potential for exaggerated statistical significance
only the most relevant effect size results are reported. The greatest effect sizes between initial
cholesterol levels and cardiovascular health markers were seen for initial triglycerides (r(842) =
.446, r2 = .199, p < .001) and initial LDL levels (r(793) = .884, r2 = .781, p < .001). These
relationships indicated that initial cardiovascular levels explained 19.9% and 78.1% of observed
initial triglyceride and LDL levels, respectively. Additionally, a negative relationship was
observed between initial total cholesterol and the initial HDL/LDL ratio (r(792) = -.433, r2 =
.187, p < .001). Patients with higher initial levels of cholesterol experienced limited
improvement in triglycerides (r(761) = -.292, r2 = .085, p < .001) and LDL levels (r(703) = .370, r2 = .137, p < .001) when compared with those who had lower initial cholesterol levels.
Relationships between initial total cholesterol and initial systolic blood pressure, initial weight,
HDL change, pulse rate change, and systolic and diastolic blood pressure changes did not reach
significance at the α = .01 level. For a correlations matrix see Table 5.
Total Cholesterol Change
When determining the efficacy of a treatment program, the amount of total cholesterol
change evidenced over the course of treatment is certainly important; however, when such a
treatment program is viewed from a holistic perspective, an integrated analysis of the

	
  

CHOLESTEROL CHANGES

11

relationship between total cholesterol change and other cardiovascular health-related variable
changes is even more crucial. Over the course of treatment, mean cholesterol levels dropped by
23.70 mg/dL (SD = 32.29) from 197.61 mg/dL at admittance (SD = 47.31) to 174.50 mg/dL at
discharge (SD = 42.13). Patients ages 30-39 saw the greatest drop in cholesterol levels (M = 34.96, SD = 34.89) followed by patients ages 50-59 and 40-49. For a summary of total
cholesterol change differences by age group see Figure 2. Improvement in cholesterol levels was
significantly greater (t(756) = 4.265, p < .001) for men (M = -30.11, SD = 32.41) than for women
(M = -19.93, SD = 31.52).
Although several statistically significant relationships between cholesterol change and
cardiovascular health marker changes were observed, the greatest correlated effect sizes between
cholesterol change and cardiovascular health-related variables were seen for triglyceride change
(r(761) = .472, r2 = .223, p < .001), and LDL change (r(703) = .834, r2 = .696, p < .001). This
analysis indicated that initial cardiovascular levels explained 22.3% of observed triglyceride
changes, and 69.6% of observed LDL level changes. Interestingly, a negative relationship was
observed between total cholesterol change and the HDL/LDL ratio change (r(702) = -.469, r2 =
.220, p < .001); as total cholesterol change was greater, the HDL/LDL ratio improvement was
less marked. However, even with this relationship, mean HDL/LDL ratio improvement over the
course of treatment was .047 (SD = .16) from M = .471 at admittance (SD = .23) to M = .514 at
discharge (SD = .24).
Initial HDL/LDL Ratio
As a marker for cardiovascular health, the initial HDL/LDL ratio was examined in
conjunction with demographic and other cardiovascular health-related variables in order to
describe the medical profiles of patients at admittance. Initial mean HDL/LDL ratio values (M =
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.471, SD = .23) indicated an approximate 1.00 mg/dL HDL : 2.12 mg/dL LDL concentration at
admittance. HDL/LDL ratios were significantly (t(786) = 3.516, p < .001) worse in men (M =
.437, SD = .21) than in women (M = .494, SD = .24) at admittance. There were no significant
ratio differences between age groups (F(7, 771) = 2.009, p = .052). A relationship was observed
between the initial HDL/LDL ratio and HDL levels at admittance (r(792) = .623, r2 = .388, p <
.001). A significant relationship was also noted between initial HDL/LDL ratio and LDL change
over the course of treatment (r(703) = .353, r2 = .125, p < .001). Those with higher initial
HDL/LDL ratio values experienced greater improvements in LDL during treatment; however,
mean change in LDL regardless of initial HDL/LDL profile was M = -16.16 mg/dL (SD =
23.36), and decreased from 114.42 mg/dL at admittance (SD = 36.92) to 98.25 mg/dL at
discharge (SD = 33.07). For a correlation matrix including variables with effect sizes less than
10% see Table 5.
HDL/LDL Ratio Change
As expected, the HDL/LDL ratio change was primarily related to both HDL change
(r(702) = .489, r2 = .239, p < .001) and LDL change over the course of treatment (r(702) = -.602,
r2 = .362, p < .001). Amount of HDL/LDL ratio improvement varied significantly (t(696) = 3.434, p = .001) by gender, however. Although men had poorer HDL/LDL ratios at admittance
when compared to women, men improved more (M = .074, SD = .157) during treatment than did
women (M = .031, SD = .161). Even with the more marked improvement, discharge HDL/LDL
values were still lower for men (M = .501, SD = .243) than for women (M = .523, SD = .244);
however, it is possible that with continued treatment the observed trend in men might eclipse the
gender differences at the conclusion of treatment.
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Discussion

The positive effects of the 18 day holistic cholesterol treatment program are evident;
every variable related to cardiovascular health (with the exception of HDL levels) evidenced
improvement over the course of treatment. Although the nominal HDL levels decreased during
treatment, the concurrent improvements in total cholesterol levels, LDL levels, and the
HDL/LDL ratio help explain the observed phenomenon. A wide range of patients is represented
in the sample yet improvements are seen, not just in the cholesterol profile, but also in blood
pressure, weight, and pulse rate.
As markers for cardiovascular health and CVD risk, both total cholesterol levels and the
HDL/LDL ratio were analyzed in conjunction with other cardiovascular health-related variables
such as blood pressure, weight, and amount of exercise. Both total cholesterol and the HDL/LDL
ratio were most strongly related to changes evidenced in various components of the cholesterol
profile (triglyceride and LDL levels, for example). Gender differences in the cholesterol profile
were also noted. Although initial values for total cholesterol and HDL/LDL ratio were poorer for
men than for women, men saw greater improvement in both of these variables than did women.
The total cardiovascular health-related variable improvement during the treatment
program, as well as the improvement in the cholesterol profile, provides evidence for a holistic
perspective on cardiovascular treatment regimens. Because the population included in this study
was quite large, only the greatest effect sizes were noted in this report; however, it is evident
from an analysis of the data that a lifestyle program such as this has beneficial effects for a wide
range of cardiovascular health-related variables. Even over the short duration of this program,
mean cholesterol levels improved by 23.70 mg/dL, triglycerides by 27.72 mg/dL, and systolic
blood pressure by 14.48 mmHg.
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This study opens doors for future holistic research into alternative methods of cholesterol
treatment. Notwithstanding, there are some limitations to the design of the study. First, because
the data in this study are archival, the reasons for which patients sought treatment at the program
are unknown, and the profile of patients treated may not be representative of the population
seeking statin treatment. Additionally, in quite a few patients, at least one data point was missing
from the record; although the statistical analysis was possible due to the large sample size, the
missing data points may have restricted the holistic perspective of each patient’s health changes.
Patient data was also collected over a period of time and by various physicians. This may have
introduced some error and variability into the data aggregated.
Future research possibilities include replication studies at other holistic cholesterol
treatment centers, a mixed study design investigating both the psychological and physiological
factors associated with holistic treatment programs, and an experimental study to control for the
difference in environment at the treatment center versus implementing the same lifestyle changes
in the patients’ homes. While this study is by no means exhaustive, it aims to provide a basis for
choosing a holistic treatment program as an alternative to traditional statin treatments, and works
to establish a holistic understanding of cardiovascular health due to simple lifestyle changes.
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Table 1
Summary of Patient Record Data at Admittance

Total cholesterol (mg/dL)

M
197.61

SD
47.31

# Valid cases
844

Triglycerides (mg/dL)

180.60

116.06

843

HDL (mg/dL)

47.90

14.29

842

LDL (mg/dL)

113.83

36.57

794

0.47

0.23

793

Systolic blood pressure (mmHg)

141.22

24.79

888

Diastolic blood pressure (mmHg)

79.98

14.44

892

Pulse rate (beats/minute)

76.15

12.22

889

204.70

62.55

893

.825

1.41

739

Variable

HDL/LDL ratio

Weight (lbs)
Exercise (miles/day)
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Table 2
Summary of Gender Differences in Cardiovascular Health Variables at Admittance

Variable

Men (SD)

Means
Women (SD)

t-statistic
4.988

p-value
.000

187.33 (47.03)

203.90 (46.57)

Triglycerides (mg/dL)

-1.658

n.s.

189.12 (123.15)

175.41 (111.81)

HDL (mg/dL)

11.492

.000

41.53 (11.38)

51.85 (14.43)

LDL (mg/dL)

3.678

.000

107.66 (35.59)

117.49 (36.81)

3.516

.000

0.435 (0.209)

0.494 (0.241)

1.165

n.s.

139.93 (24.40)

141.93 (25.05)

-1.042

n.s.

80.62 (16.23)

79.54 (13.20)

1.509

n.s.

75.42 (12.73)

76.69 (11.89)

-6.962

.000

222.98 (65.18)

193.07 (57.85)

-.958

n.s.

0.89 (1.40)

0.79 (1.42)

Total cholesterol (mg/dL)

HDL/LDL ratio
Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
Pulse rate (beats/minute)
Weight (lbs)
Exercise (miles/day)
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Table 3
Interactions between Cholesterol, LDL, and HDL/LDL Ratio Changes when Predicting HDL
Change

Variable

Unstandardized Coefficients
B
SE

β

t-statistic

p-value

-6.011

.000

-1.649

.274

Cholesterol change

.045

.014

.172

3.312

.001

LDL change

.127

.019

.389

6.785

.000

38.197

1.702

.803

22.441

.000

(Constant)

HDL/LDL ratio change
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Table 4
Mean Change Scores in Cardiovascular Health Variables over the Course of Treatment
Variable
Total cholesterol
(mg/dL)

Mean change
(discharge – admittance)

t-statistic

-23.695

SD
32.289

-20.270

p-value
.000

Triglycerides (mg/dL)

-27.723

80.923

-9.457

.000

HDL (mg/dL)

-2.596

8.318

-8.622

.000

LDL (mg/dL)

-16.165

23.356

-18.363

.000

0.047

0.160

7.793

.000

Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)

-14.484

19.196

-21.580

.000

-6.979

12.008

-16.653

.000

Pulse rate (beats/minute)

-4.484

10.904

-11.624

.000

-5.771

9.722

-17.121

.000

2.680

2.155

31.976

.000

HDL/LDL ratio

Weight (lbs)
Exercise (miles/day)
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Table 5
Correlations Matrix for Total Cholesterol, HDL/LDL Ratio, and Additional Cardiovascular
Health-related Variables

1. Cholesterol at admittance

Cholesterol at Cholesterol
admittance
change
—

HDL/LDL at
admittance

HDL/LDL
change

2. Cholesterol change

-.476*

—

3. HDL/LDL at admittance

-.433*

.273*

—

4. HDL/LDL change

.034

-.469*

-.255*

—

5. Triglycerides at admittance

.446*

-.292*

-.294*

.036

6. Triglyceride change

-.292*

.472*

.121*

-.213*

7. HDL at admittance

.190*

.06

.623*

-.196*

8. HDL change

-.063

.011

-.239*

.489*

9. LDL at admittance

.884*

-.371*

-.630*

.075

10. LDL change

-.370*

.834*

.353*

-.602*

11. Systolic BP at admittance

.074

-.030

-.080

.005

12. Systolic BP change

-.006

.047

.011

.003

13. Diastolic BP at admittance

.136

*

-.094

-.159

.030

14. Diastolic BP change

-.051

.064

.084

-.035

15. Pulse rate at admittance

.113*

-.081

.064

.044

16. Pulse change

-.049

.077

-.044

-.059

17. Weight at admittance

.047

-.161*

-.246*

.070

18. Weight change

-.007

.085

.099*

-.030

*

-.114

.029

.041

.037

.080

-.149*

-.087

.069

19. Exercise at admittance
20. Exercise change

Note: * = Correlation is significant at the .01 level (2-tailed).
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Figure 1
Initial Total Cholesterol Means by Age Group
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Figure 2
Total Cholesterol Mean Changes by Age Group
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